Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer

DeSnyder, Sarah M.; Mittendorf, Elizabeth A.; Le-Petross, C.; Krishnamurthy, Savitri; Whitman, Gary J.; Ueno, Naoto T.; Woodward, Wendy A.; Kuerer, Henry Mark; Akay, Catherine Liebig; Babiera, Gildy; Yang, Wei Tse; Lucci, Anthony

doi:10.1016/j.clbc.2017.06.014

Cited by 32 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most IBC are ductal carcinoma and had a high histological nuclear grade [ 13 ]. About 17 % to 30% of IBC cases are triple negative and 18% to 44% are epidermal growth factor receptor 2 (HER2) positive [ 14 ] ( Table 1 , [ 15 - 19 ]). The combination of histopathological breast data with the characteristic clinical features may confirm the diagnosis of IBC.…”

Section: Ibc Diagnosis Criteriamentioning

confidence: 99%

Inflammatory Breast Cancer: A Literature Review

et al. 2018

View full text Add to dashboard Cite

The multidisciplinary management of inflammatory breast cancer (IBC), which is the most aggressive form of breast cancer due to its rapid proliferation, has changed over the past three decades thanks to advances in medical treatments that represent the basis of treatment, without eliminating the use of locoregional treatments including surgery and radiotherapy in the localized stages. The molecular profile determination of IBC allows the orientation towards new targeted therapeutic strategies with an impact on survival.

show abstract

Section: Ibc Diagnosis Criteriamentioning

confidence: 99%

Inflammatory Breast Cancer: A Literature Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, the recommendation for the use of sentinel lymph node dissection in patients with clinically node-positive disease treated with NST, based on the results of the American College of Surgeons Oncology Group Z1071 trial, should be given with caution in IBC patients because this patient population was actively excluded from the study 43 , 44 . The results of a prospective clinical trial demonstrating failure to map in 75% of IBC patients, highlighting the importance of level I and II axillary lymph node dissection were presented 45 . There was agreement that contralateral prophylactic mastectomy should be deferred to ensure that complications related to this non-oncologic surgery do not delay radiotherapy administration.…”

Section: Introductionmentioning

confidence: 99%

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference

Ueno¹,

Fernandez²,

Cristofanilli³

et al. 2018

J. Cancer

Self Cite

View full text Add to dashboard Cite

National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program at The University of Texas MD Anderson Cancer Center in Houston Texas. A consensus on the clinical management of patients with IBC was discussed, summarized, and subsequently reviewed. All participants at the conference (patients, advocates, researchers, trainees, and clinicians) were queried using the MDRing electronic survey on key management issues. A summary of the expert consensus and participant voting is presented. Bilateral breast and nodal evaluation, breast magnetic resonance imaging, positron emission tomography/computed tomography, and medical photographs were endorsed as optimal. Neoadjuvant systemic therapy, modified radical mastectomy and level I and II ipsilateral axillary node dissection, post-mastectomy radiotherapy, adjuvant targeted therapy and hormonal therapy as indicated, and delayed reconstruction were agreed-upon fundamental premises of standard non-protocol-based treatment for IBC. Consideration for local-regional therapy in de novo stage IV IBC was endorsed to provide local control whenever feasible. Variation across centers and special circumstances were discussed.

show abstract

“…However, SLNB after systemic treatment in IBC patients remains controversial. Until now, only a few studies have assessed the identification rate (IR) and false-negativity rate (FNR) of SLNB in IBC patients having clinical axillary downstaging after receiving systemic treatment [10-12]. In these studies, IRs were low and FNRs were high.…”

Section: Introductionmentioning

confidence: 99%

Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment

et al. 2020

View full text Add to dashboard Cite

Background and Objectives: Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer treated up-front with systemic treatment. Both breast-conserving surgery and sentinel lymph node biopsy (SLNB) are controversial issues in the management of IBC. In this study, we aimed to assess the feasibility of SLNB in pathologically proven node-positive IBC patients. Methods: All patients with a histopathological diagnosis of IBC and biopsy-proven metastatic axillary lymph nodes underwent systemic treatment. Patients with a complete clinical response in the axilla who underwent SLNB followed by standard axillary dissection were analyzed. Results: The study consisted of 25 female patients. The identification rate (IR) and the false negativity rate (FNR) were 17/25 and 2/10, respectively. Overall, 9/25 and 7/25 of patients had a complete pathological response (pCR) in the breast and axilla after systemic treatment, respectively. Although the pCR in the axilla was 2/4 in nonluminal HER2-positive patients, the highest IR 4/4 and the lowest FNR 0/2 were determined in these patients. In triple-negative patients, however, the IR was 2/4 and the FNR was found to be 0/2. Conclusions: SLNB may be considered in selected axilla-downstaged IBC patients including patients with a pCR with HER2-positive and triple-negative tumors. Axillary dissection may be, therefore, omitted in those with negative SLNs.

show abstract

Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer

Cited by 32 publications

References 11 publications

Inflammatory Breast Cancer: A Literature Review

Inflammatory Breast Cancer: A Literature Review

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference

Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment

Contact Info

Product

Resources

About